Current status and future prospects for a vaccine against schistosomiasis

Expert Review of Vaccines

Volumn 3, Issue 3, 2004, Pages 315-328

  Lebens, Michael ^a   Sun, Jia Bin ^a   Czerkinsky, Cecil ^b   Holmgren, Jan ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b INSERM   (France)

Author keywords

Fecundity; Hepatosplenic; Life cycle; Praziquantel; Schistosomiasis

Indexed keywords

ANTIGEN; CHOLERA TOXIN B SUBUNIT; CYSTICIDE; DIETHYLTOLUAMIDE; GLUTATHIONE TRANSFERASE; PRAZIQUANTEL; SCHISTOSOMA HEMATOBIUM GLUTATHIONE TRANSFERASE 28 KDA; SCHISTOSOMA VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; CHRONIC DISEASE; CLINICAL TRIAL; CROSS REACTION; DISEASE COURSE; DRUG COST; DRUG DELIVERY SYSTEM; HEALTH CARE COST; HUMAN; IMMUNE RESPONSE; IMMUNITY; INFECTION; LIFE CYCLE; NONHUMAN; PATHOGENESIS; PATHOLOGY; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; SCHISTOSOMA HEMATOBIUM; SCHISTOSOMIASIS;

ANIMALS; ANTIGENS, HELMINTH; CLINICAL TRIALS; HOST-PARASITE RELATIONS; HUMANS; SCHISTOSOMA JAPONICUM; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS; VACCINATION; VACCINES;

EID: 2942720501     PISSN: 14760584     EISSN: None     Source Type: Journal    
DOI: 10.1586/14760584.3.3.315     Document Type: Review

References (86)

1. Chitsulo L, Engels D, Montresor A, Savioli L. The global status of schistosomiasis and its control. Acta Trop. 77(1), 41-51 (2000).
2. Engels D, Chitsulo L, Montresor A, Savioli L. The global epidemiological situation of schistosomiasis and new approaches to control and research. Acta Trop. 82(2), 139-146 (2002).
3. van der Werf MJ, de Vlas SJ, Brooker S et al. Quantification of clinical morbidity associated with schistosome infection in sub-Saharan Africa. Acta Trop. 86(2-3), 125-139 (2003).
4. Ross AG, Sleigh AC, Li Y et al. Schistosomiasis in the People's Republic of China: prospects and challenges for the 21st century. Clin. Microbiol. Rev. 14(2), 270-295 (2001).
5. Ross AG, Bartley PB, Sleigh AC et al. Schistosomiasis. N. Engl J. Med. 346(16), 1212-1220 (2002).
6. Bica I, Hamer DH, Stadecker MJ. Hepatic schistosomiasis. Infect. Dis. Clin. North Am. 14(3), 583-604 (2000).
7. Xiaonong Z, Minggang C, McManus D, Bergquist R. Schistosomiasis control in the 21st century. Proceedings of the international symposium on schistosomiasis, Shanghai, 4-6 July, 2001. Acta Trop. 82(2), 95-114 (2002).
8. Bergquist R, Al-Sherbiny M, Barakat R, Olds R. Blueprint for schistosomiasis vaccine development. Acta Trop. 82(2), 183-192 (2002).
9. Capron A, Capron M, Riveau G. Vaccine development against schistosomiasis from concepts to clinical trials. Br. Med. Bull. 62, 139-48 (2002).
10. Doenhoff MJ, Kusel JR, Coles GC, Cioli D. Resistance of Schistosoma mansoni to praziquan. Trans. R. Soc. Trop. Med. Hyg. 96(5), 465-469 (2002).
11. King CH, Muchiri EM, Ouma JH. Evidence against rapid emergence of praziquantel resistance in Schistosoma haematobium, Kenya. Emerg. Infect. Dis. 6(6), 585-594 (2000).
12. Gryseels B, Mbaye A, De Vlas SJ et al. Are poor responses to praziquantel for the treatment of Schistosoma mansoni infections in Senegal due to resistance? An overview of the evidence. Trop. Med. Int. Health 6(11), 864-873 (2001).
13. Ramaswamy K, He YX, Salafsky B, Shibuya T. Topical application of DEET for schistosomiasis. Trends Parasitol. 19(12), 551-555 (2003).
14. Ramaswamy K, Kumar P, He YX. A role for parasite-induced PGE2 in IL-10-mediated host immunoregulation by skin stage schistosomula of Schistosoma mansoni. J. Immunol. 165(8), 4567-4574 (2000).
15. Angeli V, Faveeuw C, Roye O et al. Role of the parasite-derived prostaglandin D2 in the inhibition of epidermal Langerhans cell migration during schistosomiasis infection. J. Exp. Med. 193(10), 1135-1147 (2001).
16. Loukas A, Jones MK, King LT, Brindley PJ, McManus DP. Receptor for Fc on the surfaces of schistosomes. Infect. Immun. 69(6), 3646-3651 (2001).
17. + lymphocytes. Science 294(5545), 1358-1361 (2001).
18. Doenhoff MJ. A role for granulomatous inflammation in the transmission of infectious disease: schistosomiasis and tuberculosis. Parasitology 115(Suppl.), S113-S125 (1997).
19. Hernandez HJ, Wang Y, Tzellas N, Stadecker MJ. Expression of class II but not class I, major histocompatibility complex molecules is required for granuloma formation in infection with Schistosoma mansoni. J. Immunol. 27(5), 1170-1176 (1997).
20. Gause WC, Urban JF Jr, Stadecker MJ. The immune response to parasitic helminths: insights from murine models. Trends Immunol. 24(5), 269-277 (2003).
21. Rutitzky LI, Hernandez HJ, Stadecker MJ. Th1-polarizing immunization with egg antigens correlates with severe exacerbation of immunopathology and death in schistosome infection. Proc. Natl Acad. Sci. USA 98(23), 13243-13248 (2001).
22. Hernandez HJ, Wang Y, Stadecker MJ. In infection with Schistosoma mansoni, B-cells are required for T-helper Type-2 cell responses but not for granuloma formation. J. Immunol. 158(10), 4832-4837 (1997).
23. Kaplan MH, Whitfield JR, Boros DL, Grusby MJ. Th2 cells are required for the Schistosoma mansoni egg-induced granulomatous response. J. Immunol. 160(4), 1850-1856 (1998).
24. Jankovic D, Kullberg MC, Noben-Trauth N et al. Schistosome-infected IL-4 receptor knockout (KO) mice, in contrast to IL-4 KO mice, fail to develop granulomatous pathology while maintaining the same lymphokine expression profile. J. Immunol. 163(1), 337-342 (1999).
25. Chiaramonte MG, Donaldson DD, Cheever AW, Wynn TA. An IL-13 inhibitor blocks the development of hepatic fibrosis during a T-helper Type-2-dominated inflammatory response. J. Clin. Invest. 104(6), 777-785 (1999).
26. Fallon PG, Richardson EJ, McKenzie GJ, McKenzie AN. Schistosome infection of transgenic mice defines distinct and contrasting pathogenic roles for IL-4 and IL-13: IL-13 is a profibrotic agent. J. Immunol. 164(5), 2585-2591 (2000).
27. Mentink-Kane MM, Cheever AW, Thompson RW et al. IL-13 receptor α 2 down-modulates granulomatous inflammation and prolongs host survival in schistosomiasis. Proc. Natl Acad. Sci. USA 101(2), 586-590 (2004).
28. Hoffmann KF, Cheever AW, Wynn TA. IL-10 and the dangers of immune polarization: excessive Type 1 and Type 2 cytokine responses induce distinct forms of lethal immunopathology in murine schistosomiasis. J. Immunol. 164(12), 6406-6416 (2000).
29. Mwatha JK, Kimani G, Kamau T et al. High levels of TNF, soluble TNF receptors, soluble ICAM-1 and IFN-γ but low levels of IL-5, are associated with hepatosplenic disease in human schistosomiasis mansoni. J. Immunol. 160(4), 1992-1999 (1998).
30. Malaquias LC, Falcao PL, Silveira AM et al. Cytokine regulation of human immune response to Schistosoma mansoni: analysis of the role of IL-4, IL-5 and IL-10 on peripheral blood mononuclear cell responses. Scand. J. Immunol. 46(4), 393-398 (1997).
31. Araujo MI, de Jesus AR, Bacellar O et al. Evidence of a T-helper Type 2 activation in human schistosomiasis. Eur. J. Immunol. 26(6), 1399-1403 (1996).
32. Wilson RA, Coulson PS. Strategies for a schistosome vaccine: can we manipulate the immune response effectively? Microbes Infect. 1(7), 535-543 (1999).
33. Pearce EJ, MacDonald AS. The immunobiology of schistosomiasis. Nature Rev. Immunol. 2(7), 499-511 (2002).
34. Hoffmann KF, Wynn TA, Dunne DW. Cytokine-mediated host responses during schistosome infections; walking the fine line between immunological control and immunopathology. Adv. Parasitol. 52, 265-307 (2002).
35. Bergquist NR. Schistosomiasis: from risk assessment to control. Trends Parasitol. 18(7), 309-314 (2002).
36. Yang HM. Comparison between schistosomiasis transmission modellings considering acquired immunity and age-structured contact pattern with infested water. Math. Biosci. 184(1), 1-26 (2003).
37. Coulson PS. The radiation-attenuated vaccine against schistosomes in animal models: paradigm for a human vaccine? Adv. Parasitol. 39, 271-336 (1997).
38. Wynn TA, Jankovic D, Hieny S, Cheever AW, Sher A. IL-12 enhances vaccine-induced immunity to Schistosoma mansoni in mice and decreases T-helper 2 cytokine expression, IgE production and tissue eosinophilia. J. Immunol. 154(9), 4701-4709 (1995).
39. Eberl M, Langermans JA, Frost PA et al. Cellular and humoral immune responses and protection against schistosomes induced by a radiation-attenuated vaccine in chimpanzees. Infect. Immun. 69(9), 5352-5362 (2001).
40. Chan MS, Woolhouse MEJ, Bundy DAP. Human schistosomiasis: potential long-term consequences of vaccination programmes. Vaccine 15(14), 1545-1550 (1997).
41. McManus DP. A vaccine against Asian schistosomiasis: the story unfolds. Int. J. Parasitol. 30(3), 265-271 (2000).
42. Wilson RA, Coulson PS. Strategies for a schistosome vaccine: can we manipulate the immune response effectively? Microbes Infect. 1(7), 535-543 (1999).
43. Harrop R, Jennings N, Mountford AP, Coulson PS, Wilson RA. Characterization, cloning and immunogenicity of antigens released by transforming cercariae of Schistosoma mansoni. Parasitology 121 (4), 385-394 (2000).
44. Eberl M, Mountford AP, Jankovic D, Beck E. Isolation of T-cell antigens by using a recombinant protein library and its application to the identification of novel vaccine candidates against schistosomiasis. Infect. Immun. 67(7), 3383-3389 (1999).
45. Harrop R, Coulson PS, Wilson RA. Characterization, cloning and immunogenicity of antigens released by lung-stage larvae of Schistosoma mansoni. Parasitology 118(6), 583-594 (1999).
46. Nyame AK, Lewis FA, Doughty BL, Correa-Oliveira R, Cummings RD. Immunity to schistosomiasis: glycans are potential antigenic targets for immune intervention. Exp. Parasitol. 104(1-2), 1-13 (2003).
47. Asahi H, Stadecker MJ. Analysis of egg antigens inducing hepatic lesions in schistosome infection. Parasitol. Int. 52(4), 361-367 (2003).
48. Bergquist RN, Colley DG. Schistosomiasis vaccines: research to development. Parasitol. Today 14(3), 99-104 (1998).
49. Al-Sherbiny M, Osman A, Barakat R et al. In vitro cellular and humoral responses to Schistosoma mansoni vaccine candidate antigens. Acta Trop. 88(2), 117-130 (2003).
50. Hota-Mitchell S, Siddiqui AA, Dekaban GA et al. Protection against Schistosoma mansoni infection with a recombinant baculovirus-expressed subunit of calpain. Vaccine 15(15), 1631-1640 (1997).
51. Argiro LL, Kohlstadt SS, Henri SS et al. Identification of a candidate vaccine peptide on the 37 kDa Schistosoma mansoni GAPDH. Vaccine 18(19), 2039-2048 (2000).
52. McManus DP, Wong JY, Zhou J et al. Recombinant paramyosin (rec-Sj-97) tested for immunogenicity and vaccine efficacy against Schistosoma japonicum in mice and water buffaloes. Vaccine 20(5-6), 870-878 (2001).
53. Yang W, Jackson DC, Zeng Q, McManus DP. Multi-epitope schistosome vaccine candidates tested for protective immunogenicity in mice. Vaccine 19(1), 103-113 (2000).
54. Hirsch C, Zouain CS, Alves JB, Goes AM. Induction of protective immunity and modulation of granulomatous hypersensitivity in mice using PIII, an anionic fraction of Schistosoma mansoni adult worm. Parasitology 115 (1), 21-28 (1997).
55. Zouain CS, Gustavson S, Oliveira SC et al. The role of IL-10 and IgG1 in the protection and granulomatous response in Schistosoma mansoni P24-immunized mice. Vaccine 19(9-10), 1218-1224 (2000).
56. Li Y, Auliff A, Jones MK, Yi X, McManus DP. Immunogenicity and immunolocalization of the 22.6 kDa antigen of Schistosoma japonicum. Parasite Immunol. 22(8), 415-424 (2000).
57. Al-Sherbiny MM, Galal IF, Karim AM, Ashour AA, Saad AH. Cellular and humoral immune responses to recombinant Smp 17.7 Schistosoma mansoni antigen. J. Egypt Soc. Parasitol. 33(3), 925-946 (2003).
58. Chlichlia K, Bahgat M, Ruppel A, Schirrmacher V. DNA vaccination with asparaginyl endopeptidase (Sm32) from the parasite Schistosoma mansoni: antifecundity effect induced in mice. Vaccine 20(3-4), 439-447 (2001).
59. Verity CK, McManus DP, Brindley PJ. Vaccine efficacy of recombinant cathepsin D aspartic protease from Schistosoma japonicum. Parasite Immunol. 23(3), 153-162 (2001).
60. Eberl M, Beck E, Coulson PS et al. IL-18 potentiates the adjuvant properties of IL-12 in the induction of a strong Th1 type immune response against a recombinant antigen. Vaccine 18(19), 2002-2008 (2000).
61. Argiro L, Henri S, Dessein H, Dessein AJ, Bourgois A. Induction of a protective immunity against Schistosoma mansoni with ovalbumin-coupled Sm37-5 coadsorbed with granulocyte-macrophage colony stimulating factor (GM-CSF) or IL-12 on alum. Vaccine 17(1), 13-18 (1999).
62. Argiro L, Henri S, Dessein H et al. Induction of a protection against S. mansoni with a MAP containing epitopes of Sm37-GAPDH and Sm10-DLC. Effect of coadsorption with GM-CSF on alum. Vaccine 18(19), 2033-2038 (2000).
63. Waine GJ, Yang W, Scott JC, McManus DP, Kalinna BH. DNA-based vaccination using Schistosoma japonicum (Asian blood-fluke) genes. Vaccine 15(8), 846-848 (1997).
64. Mohamed MM, Shalaby KA, LoVerde PT, Karim AM. Characterization of Sm20.8, a member of a family of schistosome tegumental antigens. Mol. Biochem. Parasitol. 96(1-2), 15-25 (1998).
65. Waine GJ, Mazzer DR, McManus DP. DNA immunization by intramuscular injection or gene gun induces specific IgG antibodies against a Schistosoma japonicum 22 kDa antigen, Sj22, when fused to the murine Ig K-chain secretory leader sequence. Parasite Immunol. 21(1), 53-56 (1999).
66. Waine GJ, Alarcon JB, Qiu C, McManus DP. Genetic immunization of mice with DNA encoding the 23 kDa transmembrane surface protein of Schistosoma japonicum (Sj23) induces antigen-specific immunoglobulin G antibodies. Parasite Immunol. 21(7), 377-381 (1999).
67. Chlichlia K, Bahgat M, Ruppel A, Schirrmacher V. DNA vaccination with asparaginyl endopeptidase (Sm32) from the parasite Schistosoma mansoni: antifecundity effect induced in mice. Vaccine 20(3-4), 439-447 (2001).
68. Chlichlia K, Bahgat M, Schirrmacher V, Ruppel A. Species-restricted antibody response against a DNA-construct coding for aspartic proteinase from Schistosoma japonicum. Parasitol. Res. 88(4), 368-375 (2002).
69. Da'Dara AA, Skelly PJ, Walker CM, Harn DA. A DNA-prime/protein-boost vaccination regimen enhances Th2 immune responses but not protection following Schistosoma mansoni infection. Parasite Immunol. 25 (8-9), 429-437 (2003).
70. Da'dara AA, Skelly PJ, Wang MM, Harn DA. Immunization with plasmid DNA encoding the integral membrane protein, Sm23, elicits a protective immune response against schistosome infection in mice. Vaccine 20(3-4), 359-369 (2001).
71. Czerkinsky C, Sun JB, Lebens M et al. Cholera toxin B subunit as transmucosal carrier-delivery and immunomodulating system for induction of anti-infectious and antipathological immunity. Ann. NY Acad. Sci. 778, 185-193 (1996).
72. Sun JB, Mielcarek N, Lakew M et al. Intranasal administration of a Schistosoma mansoni glutathione-S-transferase-cholera toxoid conjugate vaccine evokes antiparasitic and antipathological immunity in mice. J. Immunol. 163(2), 1045-1052 (1999).
73. Lebens M, Sun JB, Sadeghi H et al. A mucosally administered recombinant fusion protein vaccine against schistosomiasis protecting against immunopathology and infection. Vaccine 21(5-6), 514-520 (2003).
74. Stadecker MJ. The development of granulomas in schistosomiasis: genetic backgrounds, regulatory pathways and specific egg antigen responses that influence the magnitude of disease. Microbes Infect. 1(7), 505-510 (1999).
75. Sun JB, Stadecker MJ, Mielcarek N et al. Nasal administration of Schistosoma mansoni egg antigen-cholera B subunit conjugate suppresses hepatic granuloma formation and reduces mortality in S. mansoni-infected mice. Scand. J. Immunol. 54(5), 440-447 (2001).
76. Hernandez HJ, Rutitzky LI, Lebens M, Holmgren J, Stadecker MJ. Diminished immunopathology in Schistosoma mansoni infection following intranasal administration of cholera toxin B-immunodominant peptide conjugate correlates with enhanced transforming growth factor-beta production by CD4 T-cells. Parasite Immunol. 24(8), 423-427 (2002).
77. Ribeiro de Jesus A, Araujo I, Bacellar O et al. Human immune responses to Schistosoma mansoni vaccine candidate antigens. Infect. Immun. 68(5), 2797-2803 (2000).
78. + T-cells of schistosomiasis naturally resistant individuals living in an endemic area produce interferon-γ and tumour necrosis factor-α in response to the recombinant 14 kDA Schistosoma mansoni fatty acid-binding protein. Scand J. Immunol. 51(6), 595-601 (2000).
79. McManus DP, Ross AG, Williams GM et al. HLA class II antigens positively and negatively associated with hepatosplenic schistosomiasis in a Chinese population. Int. J. Parasitol. 31(7), 674-680 (2001).
80. Ellis JT, Morrison DA, Reichel MP. Genomics and its impact on parasitology and the potential for development of new parasite control methods. DNA Cell Biol. 22(6), 395-403 (2003).
81. Lehner T, Stanford MR, Phipps PA et al. Immunopathogenesis and Prevention of Uveitis with the Behçet's Disease-Specific Peptide Linked to Cholera Toxin B in Admatiades-Behçet's Disease. Zouboulis CC (Ed.), Kluwer Academic/Plenum Publishers, NY, USA, 173-180 (2003).
82. Todd CW, Colley DG. Practical and ethical issues in the development of a vaccine against schistosomiasis mansoni. Am. J. Trop. Med. Hyg. 66(4), 384-358 (2002).
83. Pearce EJ. Progress towards a vaccine for schistosomiasis. Acta Trop. 86(2-3), 309-313 (2003).
84. World Health Organization. The prevention and control of schistosomiasis and soil-transmitted helminthiasis. WHO Technical Report Series 912, 23 (2002).
85. Hagan P, Sharaf O. Schistosomiasis vaccines. Expert Opin. Biol. Ther. 3(8), 1271-1278 (2003).
86. Appleton CC, Mbaye A. Praziquantel-quality, dosages and markers of resistance. Trends Parasitol. 17(8), 356-357 (2001).